Four reports came the past week: IVISYS on Monday, AroCell on Tuesday, Nexam on Thursday, and A1M Pharma on Friday. None of the reports contained large surprises – and for three of them turnover was – as expected none or very close to no turnover. In my post prior to the report season I predicted that Nexam could be a winner after the report, if sales went up in Q4.
Judged by the share price, the market liked the report of A1M Pharma – and disliked the reports from IVISYS – and Nexam.
If I compare the share prices on the two Fridays 12th and 19th, the effects of the reports are visible. During the week, the OMXSPI (Broad Stockholm Index) went up 5.6 %. Compared to that A1M Pharma went up 9.4 % and came out as a winner. AroCell went 2.8 % up – up less than the market. Nexam went down 6.2 % after the report and IVISYS 8.5 %.
In my investments in growth shares, I operate with different position sizes: small positions on my ‘observation list’ – this is companies far away from the market. A1M Pharma is one, Cantargia another. In companies closer to market, I take larger positions. This year both Nexam and Heliospectra are companies were I plan to enlarge my position, since my judgement is that they will get a breakthrough on their markets during this year. Prior to the report, I bought more shares in Nexam, but on the short term, it was the wrong moment. A few words on the individual reports: Continue reading →
February is the months for year-end reports. The year circle of many companies follows the calendar, and throughout February, they are published – with a few in January and a few in March.
For growth shares at an early stage of their development the year-end reports is not the main driver of the share price. For lager companies guidance given in reports often have an impact on the share price. The share price development of growth shares are governed more by non-financial press releases: a CE-marking, an initial order, a FDA-approval etc. than by financial results.
Of my portfolio, I expect the share price of Nexam will gain by the report – with Fortnox, G5 Entertainment, Heliospectra, and Recyctec as probable benefactors. Continue reading →
December was a green month – in more than one sense. The weather was warm and my lawn seemed to grow in both November and December, but more interesting the predominant colour in my portfolio performance for December is green.
In this post, I will evaluate the portfolio performance in December (and in 2015) and give a few comments of what to expect in 2016. The performance first. Continue reading →
I might need the services of Sherlock Holmes, and I guess that Dr. Watson would record this peculiar case as: The mystery of the vanished Shares. Some of my shares seems simply to have vanish into thin air.
The shares in question are Photocat shares. As readers of this blog knows, I participated in the IPO of Photocat in October. The share is at First North Stockholm, and trading began more than two weeks ago on Friday November 20th. Unfortunately, and this is why I might need to acquire the services of Mr. Holmes, the shares are not yet in my possession after more than two weeks. Continue reading →
In general, November was a fine month. Shares went up and my portfolio performance was good with 9 out of 13 shares rising. Of the 13 shares, 6 were up more that 15%, 4 between app. 0 and 10 % and only 3 fell . On a year-to-date-basis, the portfolio is up 60 %. Continue reading →
The past weeks have been good to my portfolio. In general shares have gone up, and some quite a lot. The short news this week will follow up on new developments in AroCell, IVISYS, Recyctec, Phase Holographic and a new company on this blog: A1M Pharma which came by as a surprise, even to me. Continue reading →
In the past week, a number of press releases have occurred regarding the companies in my portfolio of growth shares. I collect these news in a portfolio short news post. Readers of my blog knows that the prime driver of share prices in growth shares lies in the press releases – and not in changed guidance as with large cap shares. Therefor the press releases are worth reading an commenting upon. This week there are news from AroCell, Heliospectra, Fortnox, CybAero, and G5 Entertainment. Continue reading →
Friday 6 November, AroCell announced a preferential rights issue. The aim is to rise 52.2 MSEK for the clinical development and validation of the cancer test-kit developed by the company. The share issue is fully guaranteed, meaning that if no current shareholders wish to invest, other investors will. Along the issue, the company announced its intention to change listing from Aktietorget to First North. Continue reading →
October was a fine month. Autumn was at its best and a few mornings with white, frosty grass reminds me that winter will soon be over us with darkness and rain. Still it is mild, and leaves are still on the trees, both green, brown, and yellow. Even a modest storm or a night of frost, may rapidly change this.
Luckily, my portfolio performed better in October than in August and September. Some shares went even exceptionally well – Phase Holographic + 94 % – and others bled – Dignitana 24 % and Recyctec – 20 %. Continue reading →
The past two weeks I have been busy with a lot of different things – but not my share portfolio. I tend to monitor it closely, but a vacation in Germany without wifi followed by a week with a seminar leaving three days for five days of work – my share portfolio was not the first thing to check when I got home. Nevertheless there is a handful of portfolio news. Continue reading →